Donate

Ustekinumab Successful Refractory Crohn's Disease

Home»Health»Intestinal Disease»Crohns»Ustekinumab Successful Refractory Crohn’s Disease

Ustekinumab Successful Refractory Crohn’s disease

Patients with Crohn’s disease who have failed to respond adequately to anti- (anti-TNF) treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind, placebo-controlled trial suggest.

Indeed, around 42% of patients achieved full clinical remission at 22 weeks after ustekinumab induction and maintenance.

“A of patients with moderate-to-severe Crohn’s disease do not have a response to treatment with TNF antagonists, and among patients who do have a response, it is often not sustained or side effects require discontinuation of therapy,” study co-author (, La Jolla, USA) and colleagues comment.

Noting that preclinical studies have implicated interleukin-12 and -23 in the pathophysiology of Crohn’s disease, they performed a clinical trial of a corresponding antagonistic , ustekinumab.

The phase II clinical trial involved in 658 patients with moderate-to-severe Crohn’s disease that was resistant to TNF treatment. During the induction phase, 526 patients were randomly assigned to receive intravenous ustekinumab (at a dose of 1, 3, or 6 mg/kg) and 132 to receive placebo.

Real Full article Ustekinumab success in refractory Crohn’s disease

News-Medical.net
By , medwireNews Reporter. Patients with Crohn’s disease who have failed to respond adequately to anti-tumor necrosis factor (anti-TNF) treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind,

You must be logged in to post a comment Login

No Guts Know Glory

IDEAS Kids

IDEAS Kids

IBD Adventures